Skip to main content


Page 5 of 7

  1. The present study aims to develop a nanoparticle encapsulating doxorubicin (DOX) and programmed death-ligand 1 (PD-L1) siRNA and evaluate its anti-tumor effects on hepatoma carcinoma (HCC).

    Authors: Hanzhang Zhu, Weijiang Zhou, Yafeng Wan, Ke Ge, Jun Lu and Changku Jia
    Citation: Cancer Nanotechnology 2020 11:15
  2. Amphiphilic block copolymers used as nanomicelle drug carriers can effectively overcome poor drug solubility and specificity issues. Hence, these platforms have a broad applicability in cancer treatment. In th...

    Authors: S. Pisano, X. Wang, J. Garcia-Parra, A. Gazze, K. Edwards, V. Feltracco, Y. Hu, L. He, D. Gonzalez, L. W. Francis, R. S. Conlan and C. Li
    Citation: Cancer Nanotechnology 2020 11:14
  3. Breast cancer is therapeutically very challenging to treat as it has the main four known genetic alterations, which result in the existence of several phenotypes leading to the difference in the mode of therap...

    Authors: Sara Al Tamimi, Sarmadia Ashraf, Tahir Abdulrehman, Aijaz Parray, Said A. Mansour, Yousef Haik and Shahnaz Qadri
    Citation: Cancer Nanotechnology 2020 11:13
  4. Breast cancer is a major cause of cancer-associated deaths in the United States. It was estimated that 12% of women in the U.S. will develop invasive breast cancer in their lifetime. The human epidermal growth...

    Authors: Bryan E. White, Molly K. White, Het Adhvaryu, Issam Makhoul, Zeid A. Nima, Alexandru S. Biris and Nawab Ali
    Citation: Cancer Nanotechnology 2020 11:12
  5. Breast cancer (BC), as the most widely recognized disease in women worldwide, represents about 30% of all cancers impacting women. This study was aimed to synthesize Cu2O nanoparticles from the cystoseira myrica ...

    Authors: Parisa Taherzadeh-Soureshjani and Mohammad Chehelgerdi
    Citation: Cancer Nanotechnology 2020 11:11
  6. Cockle shell-derived aragonite calcium carbonate nanoparticles (CACNP) have demonstrated prospect as nano-sized drug carriers for targeting cancer cells. CACNP is biocompatible, biodegradable and its biomateri...

    Authors: Kehinde Muibat Ibiyeye, Sherifat Banke Idris and Abu Bakar Zakaria Zuki
    Citation: Cancer Nanotechnology 2020 11:10
  7. The AGuIX® (NH TherAguix) nanoparticle has been developed to enhance radiotherapy treatment and provide strong MR contrast. These two properties have previously been investigated separately and progressed to clin...

    Authors: H. L. Byrne, G. Le Duc, F. Lux, O. Tillement, N. M. Holmes, A. James, U. Jelen, B. Dong, G. Liney, T. L. Roberts and Z. Kuncic
    Citation: Cancer Nanotechnology 2020 11:9
  8. Successful integration of nanotechnology into the current paradigm of cancer therapy requires proper understanding of the interface between nanoparticles (NPs) and cancer cells, as well as other key components...

    Authors: Kyle Bromma, Aaron Bannister, Antonia Kowalewski, Leah Cicon and Devika B. Chithrani
    Citation: Cancer Nanotechnology 2020 11:8
  9. Doxorubicin-loaded hollow gold nanospheres (Dox@HAuNS) are a promising technology for simultaneous trans-arterial tumor-targeted chemotherapy delivery and thermal ablation. We evaluated the efficacy of intra-a...

    Authors: Rahul A. Sheth, Xiaoxia Wen, Junjie Li, Marites P. Melancon, Xin Ji, Y. Andrew Wang, Cheng-Hui Hsiao, Diana S.-L. Chow, Elizabeth M. Whitley, Chun Li and Sanjay Gupta
    Citation: Cancer Nanotechnology 2020 11:6
  10. The aim of this study was to compare contrast enhancement of Magnevist® (gadopentate dimeglumine (Mag)) to that of PEGylated Magnevist®-loaded liposomal nanoparticles (Mag-Lnps) in pancreatic cancer patient-deriv...

    Authors: Kevin Affram, Taylor Smith, Shannon Helsper, Jens T. Rosenberg, Bo Han, Jose Trevino and Edward Agyare
    Citation: Cancer Nanotechnology 2020 11:5
  11. Nanotechnology is a frequent treatment for cancer. Nanomaterials are the vehicles which deliver drugs in smaller but equally effective quantities. The aim of this investigation is to synthesize gold nanopartic...

    Authors: M. A. González-López, E. M. Gutiérrez-Cárdenas, C. Sánchez-Cruz, J. F. Hernández-Paz, I. Pérez, J. J. Olivares-Trejo and O. Hernández-González
    Citation: Cancer Nanotechnology 2020 11:4
  12. We previously described the properties of a targeted drug delivery system (DDS) in a cell-free system. Here, in this comparative cell-based study (normal and tumor cells), we provide a quantitative analysis of...

    Authors: Marzenna Wiranowska, Rupin Singh, Rana Falahat, Eva Williams, Joseph O. Johnson and Norma Alcantar
    Citation: Cancer Nanotechnology 2020 11:3
  13. The first-line chemotherapy drug that is used to treat pancreatic ductal adenocarcinoma is gemcitabine. Unfortunately, its effectiveness is hampered by its chemo-resistance, low vascularization and drug biodis...

    Authors: Paweł Nalepa, Robert Gawecki, Grzegorz Szewczyk, Katarzyna Balin, Mateusz Dulski, Mieczysław Sajewicz, Anna Mrozek-Wilczkiewicz, Robert Musioł, Jaroslaw Polanski and Maciej Serda
    Citation: Cancer Nanotechnology 2020 11:2
  14. Fluorescent silica nanoparticles have been extensively utilised in a broad range of biological applications and are facilitated by their predictable, well-understood, flexible chemistry and apparent biocompati...

    Authors: Vladimir Gubala, Giorgia Giovannini, Filip Kunc, Marco P. Monopoli and Colin J. Moore
    Citation: Cancer Nanotechnology 2020 11:1
  15. In recent years, disease treatment has evolved strategies that require increase in pharmaceutical agent’s efficacy and selectivity while decreasing their toxicity in normal tissues. These requirements have led...

    Authors: Esteban Beltrán-Gracia, Adolfo López-Camacho, Inocencio Higuera-Ciapara, Jesús B Velázquez-Fernández and Alba A Vallejo-Cardona
    Citation: Cancer Nanotechnology 2019 10:11
  16. A wide range of nanoparticles (NPs), composed of different elements and their compounds, are being developed by several groups as possible radiosensitisers, with some already in clinical trials. However, no sy...

    Authors: Alexandra Guerreiro, Nicholas Chatterton, Eleanor M. Crabb and Jon P. Golding
    Citation: Cancer Nanotechnology 2019 10:10
  17. Heat generated from plasmonic nanoparticles can be utilized in plasmonic photothermal therapy. A combination of near-infrared laser and plasmonic nanoparticles is compelling for the treatment of brain cancer, ...

    Authors: Yue He, Kristoffer Laugesen, Dana Kamp, Salik A. Sultan, Lene B. Oddershede and Liselotte Jauffred
    Citation: Cancer Nanotechnology 2019 10:8
  18. Nanocarriers have the potential to improve the therapeutic index of currently available drugs by increasing drug efficacy, lowering drug toxicity and achieving steady-state therapeutic levels of drugs over an ...

    Authors: Natalia Lemos Chaves, Danilo Aquino Amorim, Cláudio Afonso Pinho Lopes, Irina Estrela-Lopis, Julia Böttner, Aparecido Ribeiro de Souza and Sônia Nair Báo
    Citation: Cancer Nanotechnology 2019 10:7
  19. Ion-beam cancer therapy, an alternative to a common radiation therapy with X-rays, has been used clinically around the world since 1990s; the number of proton therapy centers as well as facilities using heavie...

    Authors: Eugene Surdutovich and Andrey V. Solov’yov
    Citation: Cancer Nanotechnology 2019 10:6
  20. Relative biological effectiveness (RBE) is a key quantity for the description of radiobiological effects induced by charged-particle irradiation in the context of ion-beam cancer therapy. Since RBE is a comple...

    Authors: Alexey Verkhovtsev, Eugene Surdutovich and Andrey V. Solov’yov
    Citation: Cancer Nanotechnology 2019 10:4
  21. This article reviews radiation chemistry processes induced by high-linear energy transfer (LET) radiation. The first part gives a short historical introduction and defines the essential concepts of radiation c...

    Authors: Gérard Baldacchino, Emilie Brun, Ibtihel Denden, Sarah Bouhadoun, Raphael Roux, Hicham Khodja and Cécile Sicard-Roselli
    Citation: Cancer Nanotechnology 2019 10:3
  22. Poly(lactic-co-glycolic acid) (PLGA) is a biodegradable and biocompatible polymer which is widely used as a matrix to incorporate therapeutic agents. The anticancer activity of targeted folate-modified docetaxel-...

    Authors: Yuri I. Poltavets, Alexander S. Zhirnik, Vasilisa V. Zavarzina, Yuliya P. Semochkina, Valentina G. Shuvatova, Anna A. Krasheninnikova, Sergey V. Aleshin, Danil O. Dronov, Eugeny A. Vorontsov, Vadim Yu. Balabanyan and Galina A. Posypanova
    Citation: Cancer Nanotechnology 2019 10:2
  23. Radiotherapy is commonly used for treating cancer. Novel sensitizers, such as gold nanoparticles (GNPs), are being used to enhance the local radiation dose. It is not known how the uptake and radiation dose en...

    Authors: Kyle Bromma, Kristy Rieck, Jayesh Kulkarni, Connor O’Sullivan, Wonmo Sung, Pieter Cullis, Jan Schuemann and Devika B. Chithrani
    Citation: Cancer Nanotechnology 2019 10:1
  24. Development of biocompatible multifunctional polymeric drug carriers is crucial in modern pharmaceutics aimed to create “smart” drugs. The high potential of the PEGylated comb-like polymeric nanocarrier (PNC) ...

    Authors: Lesya Kobylinska, Igor Patereha, Natalia Finiuk, Natalia Mitina, Anna Riabtseva, Igor Kotsyumbas, Rostyslav Stoika, Alexander Zaichenko and Sandor G. Vari
    Citation: Cancer Nanotechnology 2018 9:11
  25. A novel treatment planning framework, the Relative Biological Effective Dose (RBED), for high Z nanoparticle (NP)-enhanced photon radiotherapy is developed and tested in silico for the medical exemplar of neoa...

    Authors: Jeremy M. C. Brown, Gerard G. Hanna, Nathanael Lampe, Balder Villagomez-Bernabe, James R. Nicol, Jonathan A. Coulter and Fred J. Currell
    Citation: Cancer Nanotechnology 2018 9:9
  26. C60 fullerene-based nanoformulations are proposed to have a direct toxic effect on tumor cells. Previous investigations demonstrated that C60 fullerene used alone or being conjugated with chemotherapeutic agents ...

    Authors: Larysa M. Skivka, Svitlana V. Prylutska, Mariia P. Rudyk, Nataliia M. Khranovska, Ievgeniia V. Opeida, Vasyl V. Hurmach, Yuriy I. Prylutskyy, Leonid F. Sukhodub and Uwe Ritter
    Citation: Cancer Nanotechnology 2018 9:8
  27. Recently, some studies have focused on dendrimer nanopolymers as a magnetic resonance imaging (MRI) contrast agent or a vehicle for gene and drug delivery. Considering the suitable properties of these material...

    Authors: Marzieh Salimi, Saeed Sarkar, Reza Saber, Hamid Delavari, Ali Mohammad Alizadeh and Hendrik Thijmen Mulder
    Citation: Cancer Nanotechnology 2018 9:7
  28. Recent approvals of gene therapies by the FDA and the EMA for treatment of inherited disorders have further opened the door for assessment of nucleic acid pharmaceuticals for clinical usage. Arising from the p...

    Authors: Cian M. McCrudden, John W. McBride, Joanne McCaffrey, Emma M. McErlean, Nicholas J. Dunne, Vicky L. Kett, Jonathan A. Coulter, Tracy Robson and Helen O. McCarthy
    Citation: Cancer Nanotechnology 2018 9:5
  29. The combined use of radiation therapy and chemotherapy is commonly being used in cancer treatment. The side effects of the treatment can be further minimized through targeted delivery of anticancer drugs and l...

    Authors: Celina Yang, Kyle Bromma, Caterina Di Ciano-Oliveira, Gaetano Zafarana, Monique van Prooijen and Devika B. Chithrani
    Citation: Cancer Nanotechnology 2018 9:4
  30. Nowadays, viral nanoparticles (VNPs) have attracted a lot of attention, although some are concerned that VNPs may reflect on viral entry of virus into animal or plant cells. In the present study, it aimed to i...

    Authors: Neda Esfandiari, Mohsen Karimi Arzanani and Mina Koohi-Habibi
    Citation: Cancer Nanotechnology 2018 9:1
  31. Chemotherapeutic agents have limited efficacy and resistance to them limits today and will limit tomorrow our capabilities of cure. Resistance to treatment with anticancer drugs results from a variety of facto...

    Authors: Eudald Casals, Muriel F. Gusta, Macarena Cobaleda-Siles, Ana Garcia-Sanz and Victor F. Puntes
    Citation: Cancer Nanotechnology 2017 8:7
  32. Nanoparticles (NPs) have been shown to have good ability to improve the targeting and delivery of therapeutics. In the field of photodynamic therapy (PDT), this targeting advantage of NPs could help ensure dru...

    Authors: Zahraa Youssef, Régis Vanderesse, Ludovic Colombeau, Francis Baros, Thibault Roques-Carmes, Céline Frochot, Habibah Wahab, Joumana Toufaily, Tayssir Hamieh, Samir Acherar and Amirah Mohd Gazzali
    Citation: Cancer Nanotechnology 2017 8:6
  33. Early diagnosis, monitoring and treatment selection of cancer represent major challenges in medicine. The definition of the complex clinical and molecular landscape of cancer requires the combination of multip...

    Authors: Luca Guerrini, Nicolas Pazos-Perez, Eduardo Garcia-Rico and Ramon Alvarez-Puebla
    Citation: Cancer Nanotechnology 2017 8:5
  34. Small metallic nanoparticles are proposed as potential nanodrugs to optimize the performances of radiotherapy. This strategy, based on the enrichment of tumours with nanoparticles to amplify radiation effects ...

    Authors: Sha Li, Erika Porcel, Hynd Remita, Sergio Marco, Matthieu Réfrégiers, Murielle Dutertre, Fabrice Confalonieri and Sandrine Lacombe
    Citation: Cancer Nanotechnology 2017 8:4
  35. Over the past two decades, there has been a significant evolution in the technologies and techniques employed within the radiation oncology environment. Over the same period, extensive research into the use of...

    Authors: Raymond B. King, Stephen J. McMahon, Wendy B. Hyland, Suneil Jain, Karl T. Butterworth, Kevin M. Prise, Alan R. Hounsell and Conor K. McGarry
    Citation: Cancer Nanotechnology 2017 8:3
  36. There has been growing interest in the use of nanomaterials for a range of biomedical applications over the last number of years. In particular, gold nanoparticles (GNPs) possess a number of unique properties...

    Authors: Soraia Rosa, Chris Connolly, Giuseppe Schettino, Karl T. Butterworth and Kevin M. Prise
    Citation: Cancer Nanotechnology 2017 8:2
  37. Radiotherapy has been an integral treatment modality for cancer. The field arose from and progressed through innovations in physics, engineering, and biology. The evolution of radiation oncology will rely on t...

    Authors: Yu Mi, Zhiying Shao, Johnny Vang, Orit Kaidar-Person and Andrew Z. Wang
    Citation: Cancer Nanotechnology 2016 7:11
  38. Cancer is first and foremost a disease of the genome. Specific genetic signatures within a tumour are prognostic of disease outcome, reflect subclonal architecture and intratumour heterogeneity, inform treatme...

    Authors: Harry W. Clifford, Amy P. Cassidy, Courtney Vaughn, Evaline S. Tsai, Bianka Seres, Nirmesh Patel, Hannah L. O’Neill, Emil Hewage and John W. Cassidy
    Citation: Cancer Nanotechnology 2016 7:10

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 4.5
    5-year Journal Impact Factor: 5.1
    Source Normalized Impact per Paper (SNIP): 0.723
    SCImago Journal Rank (SJR): 0.671

    Speed 2023
    Submission to first editorial decision (median days): 6
    Submission to acceptance (median days): 93

    Usage 2023
    Downloads: 328,851
    Altmetric mentions: 109